Alzheimer’s Disease Pipeline to Witness Large R&D Investment in the Coming Years

According to a new research report Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" published by P&S Market Research, Alzheimer’s disease currently exhibits a pipeline with 89 active drug candidates.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis

Alzheimer’s disease is a progressive brain disorder that gradually destroys thinking skills and memory, and ultimately the capability to carry out the basic tasks. Alzheimer's disease is presently ranked as the third leading cause of death in the aging population, after heart disease and cancer. Alzheimer’s is the most common form of dementia among elder adults. Dementia is the loss of behavioral abilities and cognitive functioning which results in interference with a person’s daily life and activities and can range from severe to the mild stage. As the disease progresses, protein formation take place in the brain to form structures called 'tangles' and 'plaques'. This results in the loss of networks between nerve cells and ultimately leads to the death of nerve cells and damage to brain tissue. Lack of some important chemical messengers has also been observed in patients suffering from Alzheimer's disease. These chemical messengers communicate by sending signals around the brain. When there is a lack of these messengers, the signals are not transmitted efficiently.

Alzheimer’s disease pipeline offers novel therapeutic targets for the treatment of Alzheimer’s disease.

Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample

The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=alzheimers-disease-pipeline-analysis

Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Contact: Mr. Kundan Kumar Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-free: +18887787886 (Usa/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com